Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

“We are looking forward to sharing a clinical update later this quarter from our silevertinib Phase 2 trial in newly diagnosed patients with EGFRm NSCLC,” said Mark Velleca, M.D., Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics (BDTX). “The update will include ORR and preliminary duration of treatment data, while PFS data is expected in the first half of 2026.”